Press Releases

Summary ToggleSteven C. Eror, President and CEO of ProLung, Inc., featured in PharmaVOICE 2018 Year in Preview

November 28, 2017

ProLung, Inc., the world leader in accurate, non-invasive, and radiation-free predictive analytics for rapid risk stratification of lung cancer, is pleased to share the PharmaVOICE “2018 Year in Preview: Treatment to Wellness” featuring ProLung president and CEO, Steven C. Eror.

Summary ToggleProLung, Inc. and Steven C. Eror, President and CEO, honored at the Swedish American Life Science Summit (SALSS) as Rising Star; further highlighted by Forbes.com

September 14, 2017

ProLung, Inc. and Steven C. Eror, President and CEO, were honored at the prestigious Swedish American Life Science Summit (SALSS) meeting in August 2017 as a “Rising Star.” ProLung was further highlighted by  Forbes.com ! It’s very exciting to be recognized for our mission to make a difference

Summary ToggleProLung, Inc. Announces Closing of Private Placement Transaction with Proceeds of $8.2 million

May 11, 2017

Salt Lake City, UT, May 11, 2017 —  ProLung, Inc., the leader in innovative predictive analytics technology and non-invasive tests for the risk stratification of lung cancer, announced today the successful closing of its private placement. The private offering was expected to raise $5.2

Summary ToggleProLung Selected to Participate at Upcoming Cavendish Global Health Impact Forum

May 04, 2017

Salt Lake City, UT, May 4, 2017 —   ProLung, Inc. , a leader in innovative predictive analytics technology and non-invasive biomarkers for the risk stratification of lung cancer, announced today it has been selected to present at the upcoming  Cavendish Global Health Impact Forum

Summary ToggleProLung Announces the Appointment of Dr. Robin L. Smith to its Board of Directors

February 16, 2017

Salt Lake City, Utah, February 16, 2017 –  ProLung, a predictive analytics and risk stratification company that has developed a novel, cost effective, and non-invasive test to identify cancerous and noncancerous lung nodules, announced today that Robin L.

Summary ToggleShareholder Update Letter – January 2017

January 15, 2017

Happy New Year from ProLung! 2016 has been a spectacular year. To achieve our research goals more rapidly, we assembled the most extensive team of clinical investigators of lung cancer in pulmonology. This speeds the clinical evaluation required for FDA market approval, sets the stage for rapid

Summary ToggleProLung President & CEO Meets with Gregory C. Simon

December 10, 2016

Steven C.  Eror , President and CEO of ProLung, meets with  Gregory C. Simon , White House Cancer Moonshot Task Force, Executive Director in the Office of the Vice President.

Summary ToggleProLung CEO Interviewed by MergerMarket’s U.S. Healthcare Editor

November 02, 2016

ProLungDX seeks funds for cancer test; sees eventual IPO – CEO Proprietary Intelligence ProLungDX , a maker of lung cancer detection devices, is looking to raise USD 5.25m from high net worth investors for US commercial development in advance of an expected initial public offering or trade sale,

Summary ToggleProLungdx Unveils its EPN Scan® at the BIO Investor Forum: Long-Awaited Test for those at Risk of Lung Cancer

October 13, 2016

Salt Lake City, UT, USA, October 13, 2016 –  ProLungdx™ today announced plans to present its leading-edge innovation for patients at risk of lung cancer during the 2016 BIO Investor Forum in San Francisco, California October 18 and 19, 2016. For the first time in an international biotech